Dexcom (DXCM) Net Equity Issued and Repurchased (2010 - 2026)

Dexcom (DXCM) has 17 years of Net Equity Issued and Repurchased data on file, last reported at $12.7 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased fell 10.56% year-over-year to $12.7 million in Q1 2026; TTM through Mar 2026 was $26.6 million, a 8.28% decrease from a year earlier, with the FY2025 full-year figure at $28.1 million, changed 0.35% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $12.7 million, down from $13.9 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for DXCM reached as high as $14.8 million in Q3 2024 and fell as low as $10.1 million in Q1 2022.
• Historically, Net Equity Issued and Repurchased has averaged $13.1 million across 5 years, with a median of $13.4 million in 2024.
• Across the five-year window, Net Equity Issued and Repurchased advanced 21.78% in 2023 and fell 10.56% in 2026, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $12.4 million in 2022, then advanced by 15.32% to $14.3 million in 2023, then advanced by 3.5% to $14.8 million in 2024, then decreased by 6.08% to $13.9 million in 2025, then retreated by 8.63% to $12.7 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $12.7 million in Q1 2026, $13.9 million in Q3 2025, and $14.2 million in Q1 2025.